The effect of oral contraceptive use on the prognosis of node positive breast cancer patients

European Journal of Cancer

Volumn 34, Issue 9, 1998, Pages 1348-1351

  Sauerbrei, W ^a   Blettner, M ^b   Schmoor, C ^a   Bojar, H ^c   Schumacher, M ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Node positive breast cancer; Oral contraceptive use; Prognosis; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EARLY DIAGNOSIS; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; META ANALYSIS; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TUMOR VOLUME;

ADULT; AGE DISTRIBUTION; BREAST NEOPLASMS; COHORT STUDIES; CONTRACEPTIVES, ORAL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 0032146174     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00139-7     Document Type: Article

References (14)

1. 1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996, 347, 1713-1727.
2. 2. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception 1996, 54(Suppl.), 1S-106S.
3. 3. Spencer JD, Millis RR, Hayward M. Contraceptive steroids and breast cancer. Br Med J 1978, 1, 1024-1026.
4. 4. Holmberg L, Lund E, Bergström R, et al. Oral contraceptives and prognosis in breast cancer: effects of duration, latency, recency, age at first use and relation to parity and body mass index in young women with breast cancer. Eur J Cancer 1994, 30A, 351-354.
5. 5. Matthews PN, Millis RR, Hayward JL. Breast cancer in women who have taken contraceptive steroids. Br Med J 1981, 282, 774-776.
6. 6. Kay CR, Hannaford PC. Breast cancer and the pill - a further report from the Royal College of General Practitioners' oral contraceptive study. Br J Cancer 1988, 58, 675-680.
7. 7. Ranstam J, Olsson H, Garne J-P, et al. Survival in breast cancer and age at start of oral contraceptive usage. Anticancer Res 1991, 11, 2043-2046.
8. 8. Rosner D, Lane WL. Oral contraceptive use has no adverse effect on the prognosis of breast cancer. Cancer 1986, 57, 591-596.
9. 9. Vessey MP, Doll R, Jones K, et al. An epidemiological study of oral contraceptives and breast cancer. Br Med J 1979, 1, 1757-1760.
10. 10. Schönborn I, Nischan P, Ebeling K. Oral contraceptive use and the prognosis of breast cancer. Breast Cancer Res Treat 1994, 30, 283-292.
11. 11. Schönborn I, Minguillon C, Zschiesche W, et al. C-erbB-2, PCNA und histomorphologische Faktoren beim Mammakarzinom nach Einnahme oraler Kontrazeptiva. Pathologe 1996, 17, 202-207.
12. 12. Schmoor C, Olschewski M, Schumacher M. Randomized and non-randomized patients in clinical trials: experiences with comprehensive cohort studies. Stat Med 1996, 15, 263-271.
13. 13. Schumacher M, Bastert G, Bojar H, et al. for the German Breast Cancer Study Group. Randomized 2 × 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. J Clin Oncol 1994, 12, 2086-2093.
14. 14. Altman DG. Practical Statistics for Medical Research. London, Chapman and Hall, 1991.